Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide

Acta Neurologica Belgica

Volumn 108, Issue 4, 2008, Pages 131-134

  Neyns, Bart ^a   Hoorens, Anne ^a   Stupp, Roger ^b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Glioblastoma; Hepatotoxicity; Idiosyncratic; Temozolomide; Valproic acid

Indexed keywords

BILIRUBIN; CILENGITIDE; ETIRACETAM; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; METHYLPREDNISOLONE; TEMOZOLOMIDE; VALPROIC ACID;

ADJUVANT THERAPY; ADULT; ANAMNESIS; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN EDEMA; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CASE REPORT; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; GLIOBLASTOMA; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; RETREATMENT; SEIZURE; SIDE EFFECT;

EID: 59949093755     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. GREWAL J., DELLINGER C. A., YUNG W. K. Fatal reactivation of hepatitis B with temozolomide. N. Engl. J. Med., 2007, 356:1591-1592.
2. CHHEDA M. G., DRAPPATZ J., GREENBERGER N. J. et al. Hepatitis B reactivation during glioblastoma treatment with temozolomide:a cautíonary note. Neurology, 2007, 68:955-956.
3. NABORS L. B., MIKKELSEN T., ROSENFELD S. S. et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol., 2007, 25:1651-1657.
4. MUTTER N., STUPP R. Temozolomide:a milestone in neuro-oncology and beyond ? Expert Rev. Anti-cancer Ther., 2006, 6:1187-1204.
5. STUPP R., MASON W. P., VAN DEN BENT M. J. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352:987-996.
6. LEE W. M. Drug-induced hepatotoxicity. N. Engl. J. Med., 2003, 349:474-485.
7. ZIMMERMAN H. J., ISHAK K. G. Valproate-induced hepatic injury:aNalyses of 23 fatal cases. Hepatology, 1982, 2:591-597.
8. TREMONT-LUKATS I. W., RATILAL B. O. et al. (2008). "Antiepileptic drugs for preventing seizures in people with brain tumors." Cochrane Database Syst. Rev. (2):CD004424.
9. STUPP R., DIETRICH P. Y., OSTERMANN KRALIEVIC S. et al. Promising survival for patients with newly diagnosed glioblastoma. multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin. Oncol., 2002, 20: 1375-1382.
10. GANIERE V., CHRISTEN G., BALLY F. et al. Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. Nat. Clin. Pract. Oncol., 2006, 3: 339-343, quiz following 343.
11. TOSONI A., CAVALLO G., ERMANI M. et al. Is protracted low-dose temozolomide feasible in glioma patients ? Neurology, 2006, 66:427-429.
12. NEYNS B., CHASKIS C., JOSSENS E. et al. A Multi-center Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma. Cancer Invest., 2008, 26:269-277.
13. Su Y. B., SOHN S., KROWN S. E. et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide:a toxicity with therapeutic implications. J. Clin. Oncol., 2004, 22:610-616.
14. SCHWARZBERG A. B., STOVER E. H., SENGUPTA T. et al. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temo-zolomide. Cancer Invest., 2007, 25:249-255.